Healthcare Industry News: Mylan
News Release - October 30, 2007
Mylan Announces Appointment of Joseph F. Haggerty as Senior Vice President and Global General CounselPITTSBURGH, Oct. 30 (HSMN NewsFeed) -- Mylan Inc. (NYSE: MYL ) today announced the appointment of Joseph F. Haggerty as Senior Vice President and Global General Counsel. As Global General Counsel, Mr. Haggerty will manage and oversee all legal issues and the provision of legal services, counsel and advice globally to all members of Mylan's senior management in their various roles across the Company.
Mr. Haggerty joins Mylan from Sanofi-Aventis U.S. Inc. where he served as Vice President, General Counsel, and Corporate Secretary. He joined Sanofi-Aventis after serving as Vice President and General Counsel for U.S. Commercial Operations at Aventis Pharmaceuticals, which was acquired by Sanofi in 2004. Prior to joining Aventis, Mr. Haggerty served as Head of the Product Liability Group at Warner-Lambert Company and, prior to that, he practiced for nine years at Shearman & Sterling LLP. Mr. Haggerty joins Mylan with 23 years of litigation, commercial, and regulatory experience, including 14 years in the pharmaceutical sector.
Mylan Vice Chairman and CEO Robert J. Coury said: "In Joe, Mylan is adding yet another highly qualified, top-caliber individual to bolster our broad and deep senior management team. His broad-based litigation experience, strong background in the pharmaceutical industry, and previous experience integrating two legal departments in a post-merger environment make him uniquely qualified for this position at Mylan."
Mr. Haggerty said: "I am thrilled to be joining Mylan at this exciting time in the Company's history. I look forward to joining the already impressive global management team and supporting them and their operations with my counsel as Mylan becomes one of the leading quality generic and specialty pharmaceutical companies in the world."
Mr. Haggerty earned a JD and a Bachelor of Arts degree from St. John's University.
Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsMylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World's Need for Medicine
Statement from Mylan's Board of Directors Regarding Retirement of CEO and Board Member Heather Bresch in Conjunction with the Combination of Mylan and Upjohn, a Division of Pfizer